January 2025 in “Nanoscale” This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.
4 citations
,
March 2023 in “Journal of controlled release” This study reports that a novel bioabsorbable nano-micelle hybridized hydrogel scaffold may reduce postoperative melanoma recurrence and mitigate the side effects of doxorubicin in mouse models.
This study evaluated amphiphilic self-assembling peptides as drug delivery systems and found they effectively ensured prolonged release and therapeutic efficacy for timolol in glaucoma and for chemotherapy agents in cancer treatment, with significant tumor size reduction observed in animal models.
25 citations
,
June 2024 in “Pharmaceutics” This review highlights the potential of scaffold-based drug delivery systems to revolutionize oral cancer treatment by enhancing targeted and localized drug administration, reducing systemic side effects, and providing environments conducive to non-cancerous cell growth, though challenges like scalability and biocompatibility remain.
April 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” This study introduced hydrogel microneedles loaded with palladium nanoparticles, which utilize the inherent cytotoxicity of polyethyleneimine to enhance the effectiveness of doxorubicin in treating melanoma, achieving a tumor inhibition rate of up to 98% in a murine model.